Multiple endogenous receptors collectively engaged by SuperMApo components

SuperMApo is a therapeutic secretome derived from macrophages undergoing apoptosis, containing a complex mixture of anti-inflammatory mediators such as TGF-beta1, IL-10, and Annexin A1 (Bonnet et al., 2013, Journal of Immunology). These components collectively engage a variety of endogenous receptors, including Transforming growth factor beta receptors, Interleukin-10 receptors, and Formyl peptide receptor 2 (FPR2) (Perretti & D'Acquisto, 2009, Nature Reviews Immunology). This multi-target engagement promotes the resolution of inflammation, induces regulatory T cells, and inhibits the production of pro-inflammatory cytokines like TNF-alpha and IL-6 (Saas et al., 2010, Current Opinion in Organ Transplantation). Clinically, this approach is primarily investigated for the treatment of Graft-versus-Host Disease (GvHD) and other refractory inflammatory conditions where broad-spectrum immune modulation is required (Perruche et al., 2006, Nature Medicine). By mimicking the natural process of efferocytosis, SuperMApo aims to restore immune homeostasis without the global toxicity associated with traditional immunosuppressants.

Other names

SuperMApo target receptorsApoptotic macrophage secretome targetsEfferocytosis-mimetic receptors

Agonism of multiple anti-inflammatory signaling pathways (TGF-beta, IL-10, and FPR2) to induce immune tolerance and resolve inflammation.